tbuckley/cabot-search huggingface dataset:
Abstract 1122: Insulin receptor expression and survival of patients with non-small cell lung cancer
Authors: Jin-Soo Kim, Edward S. Kim, Diane Liu, J. Jack Lee, Luisa Solis, Carmen Behrens, Scott Lippman, Waun Ki Hong, Ignacio I. Wistuba, Ho-Young Lee
Journal: Cancer Research (2011)

Abstract Purpose: The purpose of this study was to characterize insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF-1R) expression in patients with non-small cell lung cancer (NSCLC). Methods: A total of 459 patients who underwent curative resection of NSCLC were studied (median follow-up duration, 4.01 years). Expression of the IR and IGF-1R protein in tumor specimens was assessed immunohistochemically using tissue microarrays. Results: The cytoplasmic IR score was higher in patients with adenocarcinoma (ADC) than in those with squamous cell carcinoma (SCC) whereas cytoplasmic IGF-1R was higher in patients with SCC than those with ADC. Neither IR nor IGF-1R expression was associated with sex, smoking history, or clinical stage. Patients with positive IR or IGF-1R expression levels had poor recurrence-free (3.8 vs. 3.3 years; 3.8 vs. 2.0 years, respectively) but similar overall survival durations. Patients with high expression levels both IR and IGF-1R had shorter recurrence-free and overall survival compared to those with low levels of IR and/or IGF-1R expression. IGF-1R and IR expressions were negatively correlated with survival duration of patients with ADC and SCC, respectively. Finally, a multivariate analysis revealed the impact of IR, but not IGF-1R, as an independent prognostic predictor of survival: hazard ratio (HR) for OS, 1.005 (95% confidence interval [CI], 1.001 – 1.010], HR for RFS, 0.608 (95% CI, 1.001 – 1.009) when tested as a continuous variable. Conclusions: Overexpression of IR, but not IGF-1R, appears to foretell a poor survival among patients with NSCLC, especially those with SCC. Thus, expression of IR has a negative prognostic value and future clinical trials with therapy interventions of IR regulation should be under the consideration for this patient population. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1122. doi:10.1158/1538-7445.AM2011-1122
Stat Bite: Brain Cancer Incidence in the Elderly, 1973-1989
Authors: B. F. Hankey
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Stat BiteBrain Cancer Incidence in the Elderly, 1973–1989 Get access Benjamin F. Hankey, Sc.D. Benjamin F. Hankey, Sc.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 3, 3 February 1993, Page 181, https://doi.org/10.1093/jnci/85.3.181-a Published: 03 February 1993
Pharmaceutical and Biotechnology Firms Tackle Health Care Reform
Authors: T. Parkins
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Pharmaceutical and Biotechnology Firms Tackle Health Care Reform Get access Troy Parkins Troy Parkins Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 8, 20 April 1994, Pages 582–584, https://doi.org/10.1093/jnci/86.8.582 Published: 20 April 1994
Rest Myocardial Perfusion Scintigraphy Showing the Invasion of the Hydatid Cyst in the Myocardium
Authors: Hasan Bozkurt, Murat Aydın, Zeki Talas, Yusuf Demir, Erdem Sürücü
Journal: Clinical Nuclear Medicine (2013)

A cardiac hydatid cyst is a rare complication of the Echinococcus infection, and it is seen in just 0.5% to 2% of all cases. Because it can cause sudden death, removing the cyst is recommended. It is important to determinate the relationship between the cyst and the intra/extracardiac structures before the operation because it is of vital importance during the operation. In our case, we showed that rest myocardial perfusion scintigraphy provided an additional contribution to anatomic imaging in that it showed the invasion of the cyst in the myocardium, which was effectively directing the course of the operation.
Abstract LB-389: The function of histone demethylase RBP2 in breast cancer metastasis and drug resistance
Authors: Jian Cao, Zongzhi Liu, Minghui Zhao, Don Nguyen, Qin Yan
Journal: Cancer Research (2012)

Abstract Metastasis and drug resistance are two major challenges in cancer therapies. The occurrence of these two events requires cancer cells to gain new mutations or change their expression profiling, or both, adapt to new environment (i.e. distal organs or drug treatments). These changes likely follow Darwin's evolutionary theory: heterogeneous of cancer cells are generated randomly and more aggressive cells are selected by the tissue environment. Stable inheritance of genome and epigenetic states could delay metastasis and drug resistance. Trimethylated lysine 4 in histone H3 (H3K4me3) is the epigenetic marker for transcriptionally active promoters and the binding site for transcriptional activators. Removing the methyl groups from trimethylated H3K4 on gene promoter regions is a common epigenetic strategy for gene silencing. The JARID1 family members are to date the only known proteins responsible for catalyzing demethylation of trimethylated H3K4. Therefore they are essential in cell differentiation and development. Even though JARID1A (RBP2) was implicated in tumorigenesis of certain cancer types, its exact roles are still poorly understood. I hypothesized that RBP2 contributes to changes of epigenetic states during the occurrence of metastasis and drug resistance. Consistent with my hypothesis, I found that RBP2 is highly expressed in metastatic breast cancer cells and Herceptin tolerant population. Loss of RBP2 decreased lung metastatic gene signature and increase drug sensitivity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-389. doi:1538-7445.AM2012-LB-389
Abstract 419: A comparison between the OV100 and Maestro fluorescence imaging systems for noninvasive detection of metastasis.
Authors: Yong Zhang, Nan Zhang, Robert M. Hoffman, Ming Zhao
Journal: Cancer Research (2013)

Abstract The OV100 (Olympus Corp.), and Maestro (Perkin-Elmer Inc.), were compared for imaging metastasis in orthotopic lung, liver, pancreas and colon nude mouse tumor models expressing RFP. Non-invasive images of tumor-bearing mice indicated that the Maestro systems outperformed the OV100 for macro imaging. Tumors could be detected earlier with the Maestro system than with the OV100. By separating skin and food autofluorescence, the Maestro provides a high-contrast image. The Maestro can produce a composite image of five unmixed components and detects tumors deeper than the OV100. The Maestro can also detect more color signals simultaneously. However, the OV100 has higher resolution and even a single cell can be imaged, for example via a skin-flap. The results of this study suggest that the two instruments are complimentary. Citation Format: Yong Zhang, Nan Zhang, Robert M. Hoffman, Ming Zhao. A comparison between the OV100 and Maestro fluorescence imaging systems for noninvasive detection of metastasis. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 419. doi:10.1158/1538-7445.AM2013-419
SAME-TT2R2 PREDICTS QUALITY OF ANTICOAGULATION IN PATIENTS WITH VENOUS THROMBOEMBOLISM: THE MAQI2 EXPERIENCE
Authors: Akash Kataruka, Xiaowen Kong, Brian Haymart, Eva Kline-Rogers, Steve Almany, Jay Kozlowski, Gregory D. Krol, Scott Kaatz, James Froehlich, Geoffrey Barnes
Journal: Journal of the American College of Cardiology (2016)
Abstract 1622: Inhibition of the acetyltransferase p300 as a novel pro-apoptotic and anti-invasion approach for treatment of prostate cancer
Authors: Frédéric R. Santer, Philipp P.S. Höschele, Su Jung Oh, Holger Erb, Jan Bouchal, Ilaria T. Cavarretta, David J. Meyers, Philip A. Cole, Zoran Culig
Journal: Cancer Research (2011)

Abstract Inhibitors of histone deacetylases have been approved for clinical application in cancer treatment. On the other hand, histone acetyltransferase inhibitors have not been investigated for their potential use in cancer therapy. In prostate cancer the histone acetyltransferases and coactivators p300 and CBP are upregulated and induce transcription of androgen-receptor responsive genes, even in the absence or in the presence of low levels of androgen receptor. To discover a potential anti-cancer effect of p300/CBP inhibition we used two different approaches: i) downregulation of p300 and CBP by specific siRNA and ii) chemical inhibition of the acetyltransferase activity by a newly developed small molecule. Knockdown of p300 by specific siRNA, but surprisingly not of CBP led to an increase of caspase-dependent apoptosis involving both extrinsic and intrinsic cell death pathways in androgen-dependent and castration-resistant prostate cancer cells. Induction of apoptosis was mediated by several pathways including inhibition of androgen-receptor responsive genes and decrease of expression levels of the NF-κB subunit p65 due to a higher turnover of the protein. Furthermore, cell invasion was decreased upon p300, but not CBP depletion and was accompanied by a lower MMP-9 transcription. Thus, p300 and CBP have differential roles in the processes of survival and invasion of prostate cancer cells. Induction of apoptosis in prostate cancer cells was confirmed by the use of the cell permeable small molecule inhibitor of p300/CBP′s acetyltransferase domain. Taken together, those results suggest that p300 inhibition is a promising approach for the development of new anti-cancer therapies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1622. doi:10.1158/1538-7445.AM2011-1622
Abstract 5084: Investigation of expression of RAD51 in biopsied specimen as a predictive factor of chemo-radiation therapy for advanced rectal cancer
Authors: Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kozo Yoshikawa, Jun Higashijima, Chie Mikami, Hideya Kashihara
Journal: Cancer Research (2011)

Abstract BACKGROUND/AIMS: Chemo-radiation therapy (CRT) has been used to improve local control and survival in patients with advanced rectal carcinoma. However, a significant proportion of patients show poor response to adjuvant CRT. We thus investigated the usefulness of RAD51 expressions as a predictive maker of the CRT response. METHODOLOGY: Twenty three biopsied specimens among forty two patients who were suffered from lower rectal cancer were investigated. All patients received preoperative CRT consisting of TS-1, concurrent with 40 Gy of pelvic irradiation before having curative radical resection. The relationship between pathological responses of the tumors after therapy and expression of RAD51 was evaluated by immunostaining of biopsied and resected specimen, and evaluated the expression of RAD51 as a predictive factor of CRT. RESULTS: Positive expression of RAD51 was observed in 14 of 23 biopsied specimens (61%), and 24 of 42 patients (57.1%) in resected specimen. All RAD51 positive case which expressed in biopsied specimen expressed RAD51 positive in resected specimen. In biopsied specimen, RAD 51 positively expressed in 62.8% (10 of 14 cases) of SD, 44.4% (4 of 9 cases) of PR, and 0% (0 of 0 case) of CR, whereas in resected specimen, RAD 51 positively expressed in 68.2% (15 of 22 cases) of SD, and 42.2% (9 of 20 cases) of PR and CR. There is a tendency of reverse correlation between clinical response and expression of RAD51. Regarding the correlation between pathological response and RAD51 expression in biopsied specimen, positive expression of RAD51 was recognized in 90% (9 of 10 cases) of Grade 1, 50% (5 of 10 cases) of Grade 2, and 0% (0 of 3 cases) of Grade 3, and in resected specimen, positive expression of RAD51 was recognized in 75.0% (15 of 20 cases) of Grade 1, 47.1% (8 of 17 cases) of Grade 2 and 20.0% (1 of 5 cases) of Grade 3. A significant reverse correlation was recognized between RAD51 expression and pathological responses both in biopsied and resected specimen.CONCLUSIONS: RAD51 expression could be one of the most important predictive factors of preoperative CRT for advanced lower rectal cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5084. doi:10.1158/1538-7445.AM2011-5084
Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer.
Authors: W. M. Sikov, C. M. Perou, M. Golshan, D. Collyar, D. A. Berry, O. M. Hahn, B. Singh, C. Hudis, E. P. Winer
Journal: Journal of Clinical Oncology (2010)

TPS110 Background: While the prognosis for patients (pts) with triple-negative breast cancer (TNBC) remains poor, survival in TNBC pts who achieve a pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) equals that of others (Liedtke, JCO 2008). Thus, pCR may be a useful surrogate to evaluate novel treatment approaches in TNBC, and may aid in the identification of characteristics predictive of response. Based on preclinical and clinical data, CALGB 40603 is designed to determine if the addition of carboplatin (Cb) and/or bevacizumab (B) to standard NAC raises the pCR rate from an estimated 35% to ≥55%. Secondary endpoints include assessment of residual cancer burden in non-pCR pts, incidence and severity of adverse events, surgical and radiation practice patterns following NAC, and disease-free and overall survival. Mandatory pretreatment research biopsies will permit assessment of the impact of intrinsic subtypes defined by gene expression array and a wide array of other genomic and classical biomarkers on clinical and pathologic response. Methods: 362 eligible pts with clinical stage II-III (excluding T4d–inflammatory breast cancer) hormone receptor-poor (estrogen and progesterone receptor expression both <10%), HER2-negative breast cancers and adequate baseline organ function will be randomly assigned to one of four treatment arms: I. Weekly paclitaxel 80 mg/m2 × 12 (wP) followed by doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 q2wks (with growth factor support) × 4 (ddAC). II. wP with B (10 mg/kg q2wks) followed by ddAC with B. III. wP with Cb (AUC 6 q3wks) followed by ddAC. IV. wP with Cb and B followed by ddAC with B. Surgery is performed 4-8 week after NAC (at least 6 weeks from the last dose of B). Post-op therapy is at the discretion of the treating physicians. Status: The study opened to accrual in July 2009, and was listed by the CTSU in February 2010. Conclusions: As the largest NAC study in TNBC, CALGB 40603 may identify an optimal preoperative regimen for future trials in this population. By linking biologic characteristics with in-breast response, the correlative studies will expand our understanding of what determines drug sensitivity in TNBC. No significant financial relationships to disclose.
The Prevention of Ventilator-Associated Pneumonia
Authors: M H Kollef
Journal: New England Journal of Medicine (1999)

Nosocomial pneumonia is a leading cause of death from hospital-acquired infections, with an associated crude mortality rate of approximately 30 percent.1 Ventilator-associated pneumonia refers specifically to nosocomial bacterial pneumonia that has developed in patients who are receiving mechanical ventilation. Ventilator-associated pneumonia that occurs within 48 to 72 hours after tracheal intubation is usually termed early-onset pneumonia; it often results from aspiration, which complicates the intubation process.2 Ventilator-associated pneumonia that occurs after this period is considered late-onset pneumonia. Early-onset ventilator-associated pneumonia is most often due to antibiotic-sensitive bacteria (e.g., oxacillin-sensitive Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pneumoniae), whereas late-onset . . .
Clinically Unrecognized Myocardial Infarction Following Surgery
Authors: Anne C. Driscoll, John H. Hobika, Benjamin E. Etsten, Samuel Proger
Journal: New England Journal of Medicine (1961)

MYOCARDIAL infarction may occur during surgery or in the postoperative period. The usual clinical picture in the postoperative period may be obscured by incisional pain, respiratory or gastrointestinal complications or by sedation. The associated objective findings of fever, elevated white-cell count and increased sedimentation rate are not diagnostically helpful, and the more recent measurements of serum enzymes — namely, serum glutamic oxalacetic transaminase and lactic dehydrogenase—are of uncertain value after surgical trauma.1 2 3 4 5 6 7 8 9 Hence, shortly after operation the electrocardiogram may provide the only evidence of acute myocardial infarction.Among the reports of postoperative myocardial infarction are those of Master et al., . . .
Reconstitution Of NK Cells After Reduced Intensity Conditioned Unrelated Cord Blood Transplantation In Patients With Acute Myeloid Leukemia: Analysis Of a Prospective Phase II Multicentric Trial On Behalf Of Societe Française De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord
Authors: Stéphanie Nguyen, Laetitia Souchet, Abla Brahmi, Stephane Vigouroux, Patrice Chevallier, Sabine Furst, Faezeh Legrand, Jacques-Olivier Bay, Gérard Socié, Patrice Ceballos, Anne Huynh, Jérôme Cornillon, Françoise Sy, Ibrahim Yakoubagha, Gérard Michel, Natacha Maillard, Genevieve Margueritte, Sebastien Maury, Madalina Uzunov, Claude Eric Bulabois, Mauricette Michallet, Laurence Clement, Charles Dauriac, Karin Bilger, Simon Tabassome, Vivien Beziat, Vanderson Rocha, Bernard Rio, Vincent Vieillard
Journal: Blood (2013)
P2-11-05: Stromal Matrix Metalloproteinase-14 Expression Correlates with the Grade and Biological Behavior of Mammary Phyllodes Tumors.
Authors: JS Lee, MH Park, JH Yoon
Journal: Cancer Research (2011)

Abstract Phyllodes tumors (PTs) of the breast are rare biphasic tumors with the potential for invasion and metastatic spread. Matrix metalloproteases (MMPs) and their tissue inhibitors of metalloproteases (TIMPs) are involved in several key aspects of tumoral growth, invasion and metastasis, but little is known of their expression in PTs. The objective of this study was to assess the expression of MMPs and TIMPs in PTs and to determine their association with grade and clinical behavior of PTs. Eighty-two PTs (50 benign, 22 borderline, and 10 malignant) were studied. Automated immunohistochemical staining for MMP-1, -2, -7, -9, -11, -13, and -14 and TIMP-1, -2, and -3 was performed using tissue microarray blocks and the expression of MMPs and TIMPs was assessed in both the stromal components. There were no significant differences in the expression of stromal MMPs and TIMPs in the three groups of PTs, except for MMP-14. There was a significant increase in stromal MMP-14 expression with increasing PT grade (P &amp;lt; 0.01). The stromal MMP-14 expression in the borderline and malignant PTs was higher than that in benign PTs (P &amp;lt; 0.05 and P &amp;lt; 0.05, respectively). Furthermore, the expression of stromal MMP-14 was associated with a higher rate of recurrence (P &amp;lt; 0.05). Our results show for the first time that stromal MMP-14 expression is associated with the grade and clinical behavior of PTs of the breast. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-11-05.
Circumferential Dissection of the Aorta
Authors: D J Piñeiro, C A Bellido
Journal: New England Journal of Medicine (1999)

Figure 1. A 68-year-old woman was admitted to the emergency room with sudden left hemiparesis. A computed tomographic scan of the brain showed an image consistent with infarction of the right frontal lobe. A transthoracic echocardiogram suggested that dissection of the ascending aorta had occurred. Transesophageal echocardiography was performed immediately thereafter and confirmed the diagnosis. A wide dissection of the proximal aorta compromised more than 270 degrees of the vessel's circumference and extended to the descending thoracic aorta. The redundant, dissected wall was plicated, producing a wave-shaped image in the transverse plane of the echocardiogram (Panel A) and duplicated aortic . . .
AB0131 Abnormality of Mesenchymal Stem Cells in Patients with Rheumatoid Arthritis
Authors: Y. Sun, R. Liu, W. Chen, X. Feng, L. Sun
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> It has been shown that human umbilical cord mesenchymal stem cells (MSCs) could provide some benefits for the treatment of rheumatoid arthritis (RA) patients with refractory disease. <h3>Objectives</h3> The aim of this study is to explore whether the MSCs from bone marrow in RA patients are defective and dysfunctional. <h3>Methods</h3> We evaluated the proliferative potential of MSCs in 7 days of culture. Cellular apoptosis, immigration and senescence were detected by using 7-AAD flow-cytometry, transwell assay and the senescence-associated β-galactosidase (SA-β-Gal) staining respectively. Cultured supernatants of MSCs from RA patients and healthy controls (HC) were collected, and analyzed for cytokine production using a protein array. The immunomodulatory capacity of MSCs on PBMCs proliferation and on the distribution of Th17, Treg and Tfh cells was also investigated. <h3>Results</h3> The growth rate was lower in RA MSCs than that in HC MSCs. RA MSCs had deficient migration ability compared to HC MSCs after 24 hours of culture. More SA-β-Gal stained cells were observed in RA MSCs, and the expression of cell cycle inhibitor p21 was higher in RA MSCs than HC MSCs. However, no significant differences were found between RA MSCs and HC MSCs in the percentage of early apoptotic and late apoptotic cells. Protein arrays showed no significant differences in the cytokine production between RA MSCs and HC MSCs. MSCs from both the RA patients and controls were able to suppress the proliferation of PBMCs, and no significant differences were found between RA MSCs and HC MSCs in regulating Treg and Tfh cells. However, the ability to inhibit Th17 cells was impaired in MSCs from RA patients. <h3>Conclusions</h3> MSCs in RA patients have abnormalities compared to those in healthy control, which may play an important role in the development of RA disease. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2194